BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
IBI362: trial readouts and FDA decisions
1 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 4 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Innovent Biologics (Suzhou) Co. Ltd.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12-31 est. | P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06884293 A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) | Overweight; Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) | active not recruiting | 479 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-09-30 est. | P1/P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT07000955 Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity | Obesity | active not recruiting | 98 |
| 2026-09-24 est. | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06862908 A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity | Obesity; Heart Failure With Preserved Ejection Fraction (HFPEF); Heart Failure With Mildly Reduced E | active not recruiting | 141 |
| 2026-09-23 | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06937749 A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Metabolic Dysfunction-associated Steatohepatitis (MASH) | active not recruiting | 181 |
| 2026-08-01 est. | P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT07469800 Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity | Overweight; Obesity; Hypertensive | recruiting | 336 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.